Guangzhou Baiyunshan Hanfang Launches MCT Overseas Warehouse Delivery Services

Expediting Global Supply for Pharmaceutical and Nutraceutical Clients with Certified Medium Chain Triglycerides

GUANGZHOU, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and health products, today announces the launch of overseas warehouse delivery services for its certified medium chain triglyceride (MCT) products. This initiative is designed to address global clients’ demands for faster, more reliable supply chains, reducing delivery lead times by up to 70% compared to direct shipping from China. The overseas warehouse network covers key markets in Europe, North America, and Southeast Asia, enabling prompt fulfillment of orders for pharmaceutical manufacturers, nutraceutical producers, and distributors worldwide.

Certified MCT Products & Supply Chain Advantages

Hanfang’s MCT products are approved as pharmaceutical-grade excipients, breaking long-term foreign monopolies in the high-end lipid market. The products meet international standards including EU CEP and US FDA US-DMF certifications, ensuring compliance with global regulatory requirements. With overseas warehouses strategically located in major markets, the company reduces delivery lead times from 30-45 days to 5-10 days, enabling clients to optimize inventory management and respond quickly to market demands.

Global Compliance & Regulatory Certifications

To ensure seamless market access, Hanfang’s MCT products hold multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications validate the products’ quality, safety, and consistency, making them suitable for use in pharmaceutical formulations, nutraceuticals, and special medical foods across Europe, North America, Asia, and other regions.

Ordering & Customization Services

Hanfang’s MCT products with overseas warehouse delivery are now available for global orders through its official website, authorized distributors, and international B2B platforms. In addition to standard products, the company offers customized MCT solutions tailored to specific client requirements, including varying purity levels and packaging specifications, to meet diverse industry needs.

Executive Quote

"The launch of our MCT overseas warehouse delivery services marks a key step in our global expansion strategy," said Xu Wendong, General Manager of Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.. "By bringing our certified products closer to our international clients, we aim to enhance supply chain efficiency and support their operational stability, reinforcing our position as a trusted partner in the global pharmaceutical and nutraceutical industries."

Industry Context & Strategic Alignment

According to Grand View Research, the global medium chain triglycerides market is projected to reach USD 4.5 billion by 2030, driven by growing demand for pharmaceutical excipients and functional food ingredients. Hanfang’s overseas delivery service aligns with this market growth, addressing the critical need for reliable, fast supply chains in the global health and pharmaceutical sectors.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to expand its overseas warehouse network to cover more emerging markets, while investing in R&D to develop innovative lipid-based products. The company aims to strengthen its global presence and provide end-to-end solutions that meet evolving client demands for high-quality, accessible pharmaceutical and health products.

About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.

Established in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a core subsidiary of China’s top 500 enterprise Guangzhou Pharmaceutical Holdings (GPH). It is a national-level specialized, sophisticated, unique, and new Little Giant enterprise, with leading R&D capabilities in high-end pharmaceutical lipid excipients. The company operates a national engineering research center for traditional Chinese medicine pharmaceutical technology and new drug development, holding over 240 patents and serving more than 1,000 clients across 20+ countries. Its mission is to achieve technological self-reliance, break bottleneck technologies, and safeguard the security of the pharmaceutical industry chain while inheriting and innovating traditional Chinese medicine to protect human health. For more information, visit http://byshanhanfang.com/.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.